c-KIT expression and correlation with chemotherapy resistance in ovarian carcinoma: An immunocytochemical study

Annals of Oncology

Volumn 15, Issue 4, 2004, Pages 594-597

  Raspollini, Maria Rosaria ^a   Amunni, G ^a   Villanucci, A ^a   Baroni, G ^a   Taddei, A ^a   Taddei, G L ^a  

^a UNIVERSITY OF FLORENCE   (Italy)

Author keywords

c KIT; Chemotherapy; Ovarian carcinoma; Prognosis; STI571

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; IMATINIB; PACLITAXEL; PARAFFIN; PROTEIN TYROSINE KINASE INHIBITOR; STEM CELL FACTOR RECEPTOR;

ADVANCED CANCER; ARTICLE; CANCER GRADING; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFICACY; FEMALE; GENE EXPRESSION; GENE OVEREXPRESSION; HUMAN; HUMAN TISSUE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; MAJOR CLINICAL STUDY; OVARY CARCINOMA; PRIORITY JOURNAL; STATISTICAL SIGNIFICANCE;

DRUG RESISTANCE, NEOPLASM; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; NEOPLASM STAGING; OVARIAN NEOPLASMS; PROTO-ONCOGENE PROTEINS C-KIT;

EID: 2342418119     PISSN: 09237534     EISSN: None     Source Type: Journal    
DOI: 10.1093/annonc/mdh139     Document Type: Article

References (26)

1. Heinrich M, Griffith DJ, Druker BJ et al. Inhibition of C-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. Blood 2000; 96: 925-932.
2. Joensuu H, Dimitrijevic S. Tyrosine kinase inhibitor imatinib (STI571) as an anticancer agent for solid tumours. Ann Med 2001; 33: 451-455.
3. Flanagan JG, Leder P. The kit ligand: a cell surface molecule altered in steel mutant fibroblasts. Cell 1990; 63: 185-194.
4. Rak Choi Y, Kim H, Ju Kang H et al. Overexpression of high mobility group box 1 in gastrointestinal stromal tumors with KIT mutation. Cancer Res 2003; 63: 2188-2193.
5. Taniguchi M, Nishida T, Hirota S et al. Effect of c-kit mutation on prognosis of gastrointestinal stromal tumors. Cancer Res 1999; 59: 4297-4300.
6. Inoue M, Kyo S, Fujita M et al. Coexpression of the c-kit receptor and the stem cell factor in gynecological tumors. Cancer Res 1994; 54: 3049-3053.
7. Wrigley E, McGown AT, Ward TH et al. C-kit receptors in ovarian tumors and the response of ovarian carcinoma cell lines to recombinant human stem cell factor. Int J Gynecol Cancer 1996; 6: 273-278.
8. Tonary AM, MacDonald EA, Faught W et al. Lack of expression of c-kit in ovarian cancers is associated with poor prognosis. Int J Cancer 2000; 89: 242-250.
9. Shaw TJ, Keszthely EJ, Tonary AM et al. Cyclic AMP in ovarian cancer cells both inhibits proliferation and increases c-KIT expression. Exp Cell Res 2002; 273: 95-106.
10. De Vita VT, Hellman S, Rosemberg SA. Cancer, Principles and Practice of Oncology, 5th edition. Philadelphia-New York-Lippincott: Raven 1997; 333-347.
11. Markman M, Kennedy A, Webster K et al. Evidence that a 'treatment-free interval of less than 6 months' does not equate with clinicilly defined platinum resistance in ovarian cancer or primary peritoneal carcinoma. J Cancer Res Clin Oncol 1998; 124: 326-328.
12. Markman M, Bookman MA. Second line treatment of ovarian cancer. Oncologist 2000; 5: 26-35.
13. Markman M. Role of chemotherapy in the management of ovarian cancer. Expert Rev Anticancer Ther 2002; 2: 90-96.
14. Lonardo F, Pass IH, Lucas DR. Immunohistochemistry frequently detects c-Kit expression in pulmonary small cell carcinoma and may help select clinical subsets for a novel form of chemotherapy. Appl Immunohistochem Mol Morphol 2003; 11: 51-55.
15. Micke P, Basrai M, Faldum A et al. Characterization of c-kit expression in small cell lung cancer: prognostic and therapeutic implications. Clin Cancer Res 2003; 9: 188-194.
16. Komdeur R, Hoekstra HJ, Molenaar WM et al. Clinicopathologic assessment of postradiation sarcomas: KIT as a potential treatment target. Clin Cancer Res 2003; 9: 2926-2932.
17. Krystal GW, Hines SJ, Organ CP. Autocrine growth of small cell lung cancer mediated by coexpression of c-kit and stem cell factor. Cancer Res 1996; 56: 370-376.
18. Hibi K, Takahashi T, Sekido Y et al. Coexpression of the stem cell factor and the c-kit genes in small-cell lung cancer. Oncogene 1991; 6: 2291-2296.
19. Heinrich MC, Blanke CD, Druker BJ, Corless CE. Inhibition of KIT tyrosine kinase activity: a novel molecular approach to the treatment of KIT-positive malignancies. J Clin Oncol 2002; 20: 1692-1703.
20. Druker BJ, Talpaz M, Resta DJ et al. Efficacy and safety of a specific inhibitor of the BCR-ABL tyrosine kinase in chronic myeloid leukemia. N Engl J Med 2001; 344: 1031-1037.
21. Druker BJ, Sawyers CL, Kantarjian H et al. Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the philadelphia chromosome. N Engl J Med 2001; 344; 1038-1042.
22. Joensuu H, Robert PJ, Sarlomo-Rikala M et al. Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor. N Engl J Med 2001; 344: 1052-1056.
23. Van Oosterom AT, Judson I, Verweij J et al. Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study. Lancet 2001; 358: 1421-1423.
24. Potti A, Moazzam N, Ramar K et al. CD117 (c-KIT) over expression in patients with extensive-stage small-cell lung carcinoma. Ann Oncol 2003; 14: 894-897.
25. Fiorentini G, Rossi S, Lanzanova G et al. Potential use of imatinib mesylate in ocular melanoma and liposarcoma expressing immunohistochemical c-KIT (CD117). Ann Oncol 2003; 14: 805.
26. Slamon DJ, Leyland-Jones B, Shak S et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. N Engl J Med 2001; 344: 783-792.